{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:15:57Z","timestamp":1790327757769,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20170622008JC"],"award-info":[{"award-number":["20170622008JC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ovarian cancer during pregnancy is relatively rare and treatment strategies are inexperienced in surgery and chemotherapy. Multidisciplinary management of advanced epithelial ovarian cancer in pregnant patients with strong desire of fertility including sufficient mental and medical understanding, perioperative consideration, intraoperative decision, chemotherapy sensitivity and follow-up after treatment can gain successful outcomes for both maternal disease and fetus\u2019s development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 34-year-old primigravidae was diagnosed with advanced epithelial ovarian tumor and then first cytoreductive surgery to resect macroscopical lesions and protect the uterus for fetus was performed following with four chemotherapy courses (docetaxel and carboplatin) before delivery and four other chemotherapy courses after delivery. Chemotherapy drugs were decided by sensitivity test and the patient\u2019s anaphylaxis. Second surgery involved cesarean section with a healthy offspring and secondary cytoreductive surgery. Operative strategies were considered to gain a balance of disease and risk for fetus. Psychosocial support was provided during the course of diagnosis and treatment for a healthy coping situation. This patient relapsed 19\u2009months after the last chemotherapy course and was treated by additional adjuvant therapy to a clinical remission. The 33-month baby boy has no evidence with disease until now. The follow-up of both mother and baby is still continuing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ovarian cancer during pregnancy has low incidence which must increase in future as women delay reproduction age. Ovarian cancer cytoreductive surgery and chemotherapy have limitation to handle conditions under a desire of fetus protection. Multidisciplinary treatment model is a therapeutic solution and a challenge for gynecological surgeons, medical oncologists, pathologists, obstetricians, neonatologists, pharmacists, anesthetist, and psychologists.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13048-019-0584-3","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T09:03:14Z","timestamp":1573462994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review"],"prefix":"10.1186","volume":"12","author":[{"given":"Tianmin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-4309","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanhui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"584_CR1","first-page":"9815","volume":"379","author":"P Morice","year":"2012","unstructured":"Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. Lancet. 2012;379:9815.","journal-title":"Lancet"},{"key":"584_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bpobgyn.2015.10.015","volume":"33","author":"Asima Mukhopadhyay","year":"2016","unstructured":"Mukhopadhyay A, Shinde A, Naik R. Ovarian cysts and cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33.","journal-title":"Best Practice & Research Clinical Obstetrics & Gynaecology"},{"key":"584_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejca.2013.12.020","volume":"50","author":"D Grimm","year":"2014","unstructured":"Grimm D, Woelber L, Trillsch F, Keller-v Amsberg G, Mahner S. Clinical management of epithelial ovarian cancer during pregnancy. Eur J Cancer. 2014;50:5.","journal-title":"Eur J Cancer"},{"key":"584_CR4","doi-asserted-by":"crossref","unstructured":"Palmer J, Jivraj S, Galimberti A, Paterson M. Serous ovarian carcinoma in pregnancy. BMJ Case Rep. 2009;2009.","DOI":"10.1136\/bcr.04.2009.1809"},{"key":"584_CR5","first-page":"4","volume":"29","author":"F Martinez","year":"2013","unstructured":"Martinez F, Devesa M, Coroleu B, Tur R, Gonzalez C, Boada M, et al. Cancer and fertility preservation: Barcelona consensus meeting. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013;29:4.","journal-title":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology"},{"key":"584_CR6","first-page":"9815","volume":"379","author":"P Morice","year":"2012","unstructured":"Morice P, Uzan C, Uzan S. Cancer in pregnancy: a challenging conflict of interest. Lancet. 2012;379:9815.","journal-title":"Lancet"},{"key":"584_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejogrb.2009.12.001","volume":"149","author":"H Marret","year":"2010","unstructured":"Marret H, Lhomme C, Lecuru F, Canis M, Leveque J, Golfier F, et al. Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010;149:1.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"584_CR8","doi-asserted-by":"crossref","unstructured":"Minig L, Otano L, Diaz-Padilla I, Alvarez Gallego R, Patrono MG, Valero de Bernabe J. Therapeutic management of epithelial ovarian cancer during pregnancy Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013;15:4.","DOI":"10.1007\/s12094-012-0963-3"},{"key":"584_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4499-y","volume":"18","author":"JF Sanchez Vega","year":"2018","unstructured":"Sanchez Vega JF, Murillo Bacilio MDR, Vintimilla Condoy AS, Palta Gonzalez AM, Crespo Astudillo JA, Mora-Bravo FG. Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker. BMC Cancer. 2018;18:1.","journal-title":"BMC Cancer"},{"key":"584_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijoa.2012.01.005","volume":"21","author":"A Palanisamy","year":"2012","unstructured":"Palanisamy A. Maternal anesthesia and fetal neurodevelopment. Int J Obstet Anesth. 2012;21:2.","journal-title":"Int J Obstet Anesth"},{"key":"584_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/GRF.0b013e3181c11f60","volume":"52","author":"TG Cheek","year":"2009","unstructured":"Cheek TG, Baird E. Anesthesia for nonobstetric surgery: maternal and fetal considerations. Clin Obstet Gynecol. 2009;52:4.","journal-title":"Clin Obstet Gynecol"},{"key":"584_CR12","first-page":"3","volume":"10","author":"M Honda","year":"2017","unstructured":"Honda M, Yamada M, Kumasaka T, Samejima T, Satoh H, Sugimoto M. Recurrence of ovarian Cancer with placental metastasis: a case report. Case Rep Oncol. 2017;10:3.","journal-title":"Case Rep Oncol"},{"key":"584_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00247-013-2858-z","volume":"44","author":"E Herskovic","year":"2014","unstructured":"Herskovic E, Ryan M, Weinstein J, Wadhwani NR. Maternal to fetal transmission of cervical carcinoma. Pediatr Radiol. 2014;44:8.","journal-title":"Pediatr Radiol"},{"key":"584_CR14","doi-asserted-by":"crossref","unstructured":"Abdalla N, Bizon M, Piorkowski R, Stanirowski P, Cendrowski K, Sawicki W. Does chemotherapy for gynecological malignancies during pregnancy cause fetal growth restriction? Biomed Res Int. 2017;2017.","DOI":"10.1155\/2017\/7543421"},{"key":"584_CR15","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2013; 24 Suppl 6:","DOI":"10.1093\/annonc\/mdt333"},{"key":"584_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/CRIAI:24:3:253","volume":"24","author":"GM Shepherd","year":"2003","unstructured":"Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"584_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.6004\/jnccn.2014.0040","volume":"12","author":"M Picard","year":"2014","unstructured":"Picard M, Matulonis UA, Castells M. Chemotherapy hypersensitivity reactions in ovarian cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2014;12:3.","journal-title":"Journal of the National Comprehensive Cancer Network : JNCCN"},{"key":"584_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000341351","volume":"83","author":"F Zagouri","year":"2012","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology. 2012;83:4.","journal-title":"Oncology."},{"key":"584_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/COC.0b013e3181a44ca9","volume":"33","author":"E Cardonick","year":"2010","unstructured":"Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol. 2010;33:3.","journal-title":"Am J Clin Oncol"},{"key":"584_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajog.2013.12.013","volume":"210","author":"JA Smith","year":"2014","unstructured":"Smith JA, Gaikwad A, Mosley S, Coffer L 2nd, Cegelski J, Alcorn JL, et al. Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy. Am J Obstet Gynecol. 2014;210:3.","journal-title":"Am J Obstet Gynecol"},{"key":"584_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00404-009-0950-2","volume":"280","author":"D Doi","year":"2009","unstructured":"Doi D, Boh Y, Konishi H, Asakura H, Takeshita T. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. Arch Gynecol Obstet. 2009;280:4.","journal-title":"Arch Gynecol Obstet"},{"key":"584_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00508-015-0726-6","volume":"127","author":"K Holzmann","year":"2015","unstructured":"Holzmann K, Kropfmuller R, Schinko H, Bogner S, Fellner F, Arzt W, et al. Lung cancer in pregnancy. Wien Klin Wochenschr. 2015;127:15\u20136.","journal-title":"Wien Klin Wochenschr"},{"key":"584_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bpobgyn.2015.10.007","volume":"33","author":"Siew-Fei Ngu","year":"2016","unstructured":"Ngu SF, Ngan HY. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33.","journal-title":"Best Practice & Research Clinical Obstetrics & Gynaecology"},{"key":"584_CR24","doi-asserted-by":"publisher","first-page":"9815","DOI":"10.1016\/S0140-6736(11)61092-1","volume":"379","author":"F Amant","year":"2012","unstructured":"Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012;379:9815.","journal-title":"Lancet"},{"key":"584_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.msec.2014.06.002","volume":"45","author":"Hongye Ye","year":"2014","unstructured":"Ye H, Karim AA, Loh XJ. Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review. Mater Sci Eng C Mater Biol Appl. 2014;45.","journal-title":"Materials Science and Engineering: C"},{"key":"584_CR26","doi-asserted-by":"crossref","unstructured":"Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. Journal of experimental & clinical cancer research : CR. 2012;31.","DOI":"10.1186\/1756-9966-31-14"},{"key":"584_CR27","first-page":"7","volume":"19","author":"SJ Edwards","year":"2015","unstructured":"Edwards SJ, Barton S, Thurgar E, Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2015;19:7.","journal-title":"Health Technol Assess"},{"key":"584_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/1534735414564425","volume":"14","author":"MT Sheu","year":"2015","unstructured":"Sheu MT, Jhan HJ, Hsieh CM, Wang CJ, Ho HO. Efficacy of antioxidants as a complementary and alternative medicine (CAM) in combination with the chemotherapeutic agent doxorubicin. Integr Cancer Ther. 2015;14:2.","journal-title":"Integr Cancer Ther"},{"key":"584_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2014.11.017","volume":"51","author":"S Mahner","year":"2015","unstructured":"Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer. 2015;51:3.","journal-title":"Eur J Cancer"},{"key":"584_CR30","doi-asserted-by":"crossref","unstructured":"Tai YH, Tai YJ, Hsu HC, Lee SP, Chen YY, Chiang YC, et al. Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. Front Pharmacol. 2017;8.","DOI":"10.3389\/fphar.2017.00800"},{"issue":"1","key":"584_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1757-2215-7-57","volume":"7","author":"Gerasimos Aravantinos","year":"2014","unstructured":"Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res. 2014;7.","journal-title":"Journal of Ovarian Research"},{"key":"584_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tjog.2015.06.014","volume":"55","author":"S Xiaoli","year":"2016","unstructured":"Xiaoli S, Mei L, Junjun B, Shu D, Zhaolian W, Jin W, et al. Assessing the quality of life of infertile Chinese women: a cross-sectional study. Taiwan J Obstet Gynecol. 2016;55:2.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"584_CR33","first-page":"1","volume":"23","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yi J, He J, Chen G, Li L, Yang Y, et al. Cognitive emotion regulation strategies as predictors of depressive symptoms in women newly diagnosed with breast cancer. Psychooncology. 2014;23:1.","journal-title":"Psychooncology."},{"key":"584_CR34","first-page":"10046","volume":"388","author":"JD Tucker","year":"2016","unstructured":"Tucker JD, Wong B, Nie J-B, Kleinman A. Rebuilding patient\u2013physician trust in China. Lancet. 2016;388:10046.","journal-title":"Lancet"},{"key":"584_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40359-018-0224-5","volume":"6","author":"F Ferrari","year":"2018","unstructured":"Ferrari F, Faccio F, Peccatori F, Pravettoni G. Psychological issues and construction of the mother-child relationship in women with cancer during pregnancy: a perspective on current and future directions. BMC Psychol. 2018;6:1.","journal-title":"BMC Psychol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0584-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T18:10:26Z","timestamp":1612289426000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0584-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"30 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent for clinical use of clinical data was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript. All authors agreed to submit this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}